Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting


Seagen Inc. (Nasdaq:SGEN) today announced that new data for ADCETRIS® (brentuximab vedotin), including five oral presentations, will be featured at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021. Data presentations will include updated safety and efficacy results from clinical trials examining the potential of ADCETRIS with novel combinations in patients with advanced stage classical Hodgkin lymphoma (HL), in patients with newly diagnosed CD30-expressing peripheral T-cell lymphoma (PTCL) and in patients with other histologies.

"We look forward to sharing new data for the continued development of ADCETRIS in combination with other therapies across patient populations," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "Additionally, initial results will be presented from our SEA-BCMA program in patients with relapsed/refractory multiple myeloma."

ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and expressed on the surface of several types of PTCL. ADCETRIS is approved in more than 75 countries for relapsed or refractory HL and systemic anaplastic large cell lymphoma (sALCL).

Presentations of Company-Sponsored ADCETRIS Trials:

Abstract Title

Abstract #

Presentation

Lead Author

The ECHELON-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

 

#135

Oral presentation /
Saturday, Dec. 11,
12:00 ? 1:30 p.m. EST

 

S. Horwitz

Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens

 

#1390

Poster presentation /
Saturday, Dec. 11,
5:30 ? 7:30 p.m. EST

 

S. Parsons

Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)?a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age

 

#1966

Poster presentation /
Saturday, Dec. 11,
5:30 ? 7:30 p.m. EST

 

D. Flora

Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma

 

#1197

Poster presentation /
Saturday, Dec. 11,
5:30 ? 7:30 p.m. EST

 

D. Taft

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary results from the single-arm phase 2 study (SGN35-027 Part B)

 

#2454

Poster presentation /
Sunday, Dec. 12,
6:00 ? 8:00 p.m. EST

 

H. Lee

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the Echelon-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective

 

#2440

Poster presentation /
Sunday, Dec. 12,
6:00 ? 8:00 p.m. EST

 

T. Phillips

Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma

 

#2467

Poster presentation /
Sunday, Dec. 12,
6:00 ? 8:00 p.m. EST

 

A. Evens

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the Echelon-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective

 

#2466

Poster presentation /
Sunday, Dec. 12,
6:00 ? 8:00 p.m. EST

 

J. Burke

SEA-BCMA, an investigational nonfucosylated monoclonal antibody: interim results of a phase 1 study in relapsed/refractory multiple myeloma patients (SGNBCMA-001)

#2740

Poster presentation /
Sunday, Dec. 12,
6:00 ? 8:00 p.m. EST

 

J. Hoffman

Trials-In-Progress

Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma (SGN35-027, Trial in Progress)

 

#1369

Poster presentation /
Saturday, Dec. 11,
5:30 ? 7:30 p.m. EST

 

I. Flinn

Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress)

 

#3564

Poster presentation /
Monday, Dec. 13,
6:00 ? 8:00 p.m. EST

 

N. Bartlett

Frontline Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin and Prednisone in Patients With Peripheral T Cell Lymphoma With Less Than 10% CD30 Expression (SGN35 032, Trial in Progress)

 

#1401

Poster presentation /
Saturday, Dec. 11,
5:30 ? 7:30 p.m. EST

 

D. Jagadeesh

Presentations of Investigator-Sponsored and Cooperative Group ADCETRIS Trials:

Abstract Title

Abstract #

Presentation

Lead Author

Brentuximab vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Expressing Peripheral T-cell Lymphomas

 

#133

Oral presentation /
Saturday, Dec. 11,
12:00 ? 1:30 p.m. EST

 

A. Herrera

The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDTASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma

 

#136

Oral presentation /
Saturday, Dec. 11,
12:00 ? 1:30 p.m. EST

 

D. Sibon

Interim results of a multicenter pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide, and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukemia/lymphoma

 

#1395

Poster presentation /

Saturday, Dec. 11,
5:30 ? 7:30 p.m. EST

 

C. Dittus

Pacific: A Phase II Study of Brentuximab vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma

 

#1408

Poster presentation /
Saturday, Dec. 11,
5:30 ? 7:30 p.m. EST

 

R. Steiner

Brentuximab vedotin plus ESHAP (BRESHAP) versus ESHAP as salvage strategy for patients with primary refractory or relapsed classical Hodgkin's Lymphoma. Preliminary results from the BRESELIBET prospective clinical

 

#2459

Poster presentation /
Sunday, Dec. 12,
6:00 ? 8:00 p.m. EST

 

A. Sureda

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in 718 Patients with Relapsed/Refractory Hodgkin Lymphoma

 

#879

Oral presentation /
Monday, Dec. 13,
6:15 ? 7:45 p.m. EST

 

J. Driessen

The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity

 

#81

 

Oral presentation /
Monday, Dec. 13,
6:15 ? 7:45 p.m. EST

 

A. Lo

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of Seagen's products and product candidates, the company's pipeline and the advancement of its research and development activities. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials, the possibility of adverse regulatory actions, and the potential for delays or setbacks in product development and the regulatory review process. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.


These press releases may also interest you

at 09:20
Stevenson Search Partners (formerly The Stevenson Group), a global life science executive search firm, announced today the launch of a company-wide rebranding, including a new name, logo, visual identity and website, to reflect its evolution into a...

at 09:20
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has received the manufacturing authorization for its new site in Rankweil, Austria. As a result of the successful inspection held by the responsible national...

at 09:20
The "Global Peptide Synthesis Market by Reagent (Resins, Amino Acid, Dyes), Equipment (Peptide Synthesizer, Chromatography, Lyophilizer), Technology (Solid-phase, Solution-phase, Hybrid & Recombinant), End-user (Pharma, Biotech, CRO), and Region -...

at 09:20
PierianDx, the global leader in clinical genomics knowledge, today announced that it has partnered with Biodesix to provide its interpretation technology platform for use with the Biodesix newly launched GeneStrat NGStm genomic test, a blood-based...

at 09:20
Inspira Technologies OXY B.H.N. Ltd.   (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that Professor Daniel Brodie, an expert in critical care medicine and extracorporeal life...

at 09:20
As The Government of Ontario prepares its 2022 Spring Budget, OIRM is raising awareness of the massive losses expected if critically important sector funding is not continued. At OIRM, we understand the unprecedented financial challenges facing...



News published on 4 november 2021 at 09:35 and distributed by: